BACKGROUND AND AIM: To establish normal values of insulin resistance, secretion and sensitivity using respectively HOMA-IR, HOMA-beta% and QUICKI indexes in healthy Italian children and adolescents, based on fasting samples. METHODS: We determined HOMA-IR, HOMA-beta% and QUICKI at baseline in 142 healthy subjects from Pediatric Centres, aged 2.7 to 19 years (10.6 +/- 3.8, Mean +/- SD), with different Tanner's pubertal Stages (TS). None had hypo/hyperglycemia (fasting plasma glucose ranging from 3.6 to 5.6 mmol/l), obesity (BMI (kg/m2) 17.9 +/- 2.4, M +/- SD), or family history for diabetes mellitus. RESULTS: The HOMA-IR index slightly increases with Tanner's stage. As regards HOMA-beta% and QUICKI, a weak variation throughout puberty was observed. No significant correlation was observed between HOMA-IR, HOM A-beta%, QUICKI and BMI-SDS or chronologic age. CONCLUSIONS: Normal values of HOMA-IR, HOMA-beta% and QUICKI are useful tools in the clinical and epidemiological practice for baseline screening and follow-up of subjects at risk for type 2 diabetes mellitus.
BACKGROUND AND AIM: To establish normal values of insulin resistance, secretion and sensitivity using respectively HOMA-IR, HOMA-beta% and QUICKI indexes in healthy Italian children and adolescents, based on fasting samples. METHODS: We determined HOMA-IR, HOMA-beta% and QUICKI at baseline in 142 healthy subjects from Pediatric Centres, aged 2.7 to 19 years (10.6 +/- 3.8, Mean +/- SD), with different Tanner's pubertal Stages (TS). None had hypo/hyperglycemia (fasting plasma glucose ranging from 3.6 to 5.6 mmol/l), obesity (BMI (kg/m2) 17.9 +/- 2.4, M +/- SD), or family history for diabetes mellitus. RESULTS: The HOMA-IR index slightly increases with Tanner's stage. As regards HOMA-beta% and QUICKI, a weak variation throughout puberty was observed. No significant correlation was observed between HOMA-IR, HOM A-beta%, QUICKI and BMI-SDS or chronologic age. CONCLUSIONS: Normal values of HOMA-IR, HOMA-beta% and QUICKI are useful tools in the clinical and epidemiological practice for baseline screening and follow-up of subjects at risk for type 2 diabetes mellitus.
Authors: Jeffrey M Saland; Lisa M Satlin; Jeanna Zalsos-Johnson; Serge Cremers; Henry N Ginsberg Journal: Kidney Int Date: 2016-05-07 Impact factor: 10.612
Authors: Amy C Wilson; Michael F Schneider; Christopher Cox; Larry A Greenbaum; Jeffrey Saland; Colin T White; Susan Furth; Bradley A Warady; Mark M Mitsnefes Journal: Clin J Am Soc Nephrol Date: 2011-10-06 Impact factor: 8.237
Authors: C Brufani; D Fintini; P Ciampalini; V Nocerino; F Crea; G Giannone; P I Patera; G Valerio; M Cappa; F Barbetti Journal: J Endocrinol Invest Date: 2011-06-07 Impact factor: 4.256
Authors: J Warolin; K R Coenen; J L Kantor; L E Whitaker; L Wang; S A Acra; L J Roberts; M S Buchowski Journal: Pediatr Obes Date: 2013-01-07 Impact factor: 4.000
Authors: P Di Bonito; C Forziato; E Sanguigno; T Di Fraia; F Saitta; M R Iardino; B Capaldo Journal: J Endocrinol Invest Date: 2010-03-10 Impact factor: 4.256
Authors: J Peplies; D Jiménez-Pavón; S C Savva; C Buck; K Günther; A Fraterman; P Russo; L Iacoviello; T Veidebaum; M Tornaritis; S De Henauw; S Mårild; D Molnár; L A Moreno; W Ahrens Journal: Int J Obes (Lond) Date: 2014-09 Impact factor: 5.095